moxifloxacin has been researched along with ponesimod in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (ponesimod) | Trials (ponesimod) | Recent Studies (post-2010) (ponesimod) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 62 | 19 | 61 |
| Protein | Taxonomy | moxifloxacin (IC50) | ponesimod (IC50) |
|---|---|---|---|
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | 0.0126 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brossard, P; Darpo, B; Dingemanse, J; Hoch, M; Stoltz, R; Zhou, M | 1 |
1 trial(s) available for moxifloxacin and ponesimod
| Article | Year |
|---|---|
Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
Topics: Action Potentials; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Receptors, Lysosphingolipid; Risk Assessment; Sphingosine-1-Phosphate Receptors; Thiazoles; Time Factors; Young Adult | 2015 |